Vulin et al. (2023) found that after treatment with the proteasome inhibitor bortezomib (BTZ) targeting the proteasome, BTZ inhibited proteasomal activity and could benefit the treatment of AD by blocking the degradation of P-gp, which could in turn inhibit the level of Aβ expression in the brain. The gene discussed is PGP; the disease is Alzheimer disease.